COMMUNIQUÉS West-GlobeNewswire

Transactions in relation to share buyback program

06/08/2019 - 11:23

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 1, 2019, in accordance with article 5 of Regulation (EU) no. 596/2014 of April 16, 2014 on [...]

Release date of six-month interim report (Q2) 2019 for ALK and audio cast

06/08/2019 - 10:00

On Tuesday, 13 August 2019, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its six-month interim report (Q2) 2019. ALK will host a meeting for analysts and institutional investors that day at 13.30 p.m. (CEST) at [...]

AroCell signs a new distributor agreement in the USA and Canada

06/08/2019 - 08:15

AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United States and Canada. [...]

Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019

06/08/2019 - 08:00

Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator Initiated first Phase 2 study with metered-dose inhaler formulation Post-period end reported positive Phase 2 data with dry [...]

Acarix AB (publ) publishes Interim Report, January – June 2019

06/08/2019 - 08:00

Acarix AB (publ) publishes Interim Report, January – June 2019 Malmö, August 6, 2019 CADScor®System Included in UK guidance for ruling out Coronary Artery Disease ”With CADScor®System we have a fantastic opportunity to [...]

ReWalk Robotics to Report Second Quarter 2019 Financial Results on August 8, 2019

06/08/2019 - 07:42

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its second quarter 2019 [...]

Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)

06/08/2019 - 07:15

Ceftobiprole met primary and secondary efficacy endpoints in the treatment of ABSSSI Ceftobiprole was well tolerated Basel, Switzerland, August 06, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today positive [...]

Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 30 June 2019

06/08/2019 - 07:07

Investor News no. 04/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 6 August 2019 Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 30 June 2019 Veloxis [...]

Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

06/08/2019 - 07:05

Dupixent ® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis U.S. FDA submission for children planned for 4Q 2019 PARIS and TARRYTOWN, NY – August [...]

Sanofi : Dupixent® (dupilumab) a montré des résultats de phase III positifs dans le traitement de la dermatite atopique sévère de l’enfant âgé de 6 à 11 ans

06/08/2019 - 07:05

Dupixent ® (dupilumab) a montré des résultats de phase III positifs dans le traitement de la dermatite atopique sévère de l’enfant âgé de 6 à 11 ans Soumission pour l’enfant auprès de la FDA des États-Unis planifiée [...]

argenx to Present at 2019 Wedbush PacGrow Healthcare Conference

06/08/2019 - 07:00

August 6, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis

06/08/2019 - 07:00

Dupixent ® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis Only biologic approved in the European Union for patients aged 12 and above with moderate-to-severe atopic [...]

Sanofi : Dupixent® (dupilumab) approuvé par la Commission européenne pour traiter la dermatite atopique modérée à sévère chez les adolescents

06/08/2019 - 07:00

Dupixent ® (dupilumab) approuvé par la Commission européenne pour traiter la dermatite atopique modérée à sévère chez les adolescents Seul médicament biologique approuvé dans l'Union européenne pour le traitement de la [...]

Cosmetic Surgery Institute Celebrates the Launch of Its SkinCeuticals® Flagship Store

06/08/2019 - 03:17

Los Angeles-based plastic surgeons Dr. Mo Zakhireh, Dr. Craig Ball, and their team opened a digital skin care boutique featuring the popular SkinCeuticals® collection PALM DESERT, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE [...]

Chapin Aesthetics Welcomes Distinguished Plastic Surgeon Dr. Noah Prince

06/08/2019 - 00:48

Dr. Scott Chapin and staff are pleased to announce the August arrival of a second physician at the Philadelphia-area Chapin Aesthetics DOYLESTOWN, Pa., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Dr. Noah Prince will be the [...]

Anchiano Therapeutics Reports Second Quarter 2019 Financial Results

05/08/2019 - 23:15

CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat [...]

STERIS Announces Financial Results for Fiscal 2020 First Quarter

05/08/2019 - 22:30

• First quarter revenue grows 9% as reported, 10% constant currency organic revenue growth; • EPS as reported increases to $0.99, adjusted EPS increases to $1.23; • Outlook updated to reflect stronger than anticipated [...]

Voyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call

05/08/2019 - 22:30

CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today [...]

Allakos Announces Proposed Public Offering of Common Stock

05/08/2019 - 22:29

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today [...]